Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 481Solid Tumor 418Advanced Solid Tumor 409Unspecified Adult Solid Tumor, Protocol Specific 350Solid Tumors 322Mesothelioma, Malignant 281Mesothelioma 244Solid Tumor, Adult 113Carcinoma, Non-Small-Cell Lung 109Retinoblastoma 81Ovarian Neoplasms 65Lung Neoplasms 61Melanoma 56Sarcoma 52Stomach Neoplasms 50Carcinoma, Renal Cell 49Colorectal Neoplasms 46Small Cell Lung Carcinoma 45Pancreatic Neoplasms 45Esophageal Neoplasms 45Neoplasms 43Uterine Cervical Neoplasms 41Breast Neoplasms 38Advanced or Metastatic Solid Tumors 35Hematopoietic and Lymphatic System Neoplasm 34Neoplasm Metastasis 33Squamous Cell Carcinoma of Head and Neck 32Advanced Malignant Solid Tumors 31Solid Tumours 30Triple Negative Breast Neoplasms 29

Interventions

darolutamide 1Rifampin 1Itraconazole 1Hydroxychloroquine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Refractory or Relapsed Solid Tumors × Other solid neoplasm × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

NCT01634893 2016-03-25

Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 1 Completed
18 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡